BR9901052A - Carboxamidas heterocìclicas. - Google Patents
Carboxamidas heterocìclicas.Info
- Publication number
- BR9901052A BR9901052A BR9901052-6A BR9901052A BR9901052A BR 9901052 A BR9901052 A BR 9901052A BR 9901052 A BR9901052 A BR 9901052A BR 9901052 A BR9901052 A BR 9901052A
- Authority
- BR
- Brazil
- Prior art keywords
- heterocyclic carboxamides
- carboxamides
- heterocyclic
- agonist
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
<B>"CARBOXAMIDAS HETEROCìCLICAS"<D>. Compostos de fórmula em que X, Y, Z, R^ 2^ e R^ 3^ são como definidos acima, úteis para o tratamento ou a prevenção de enxaquecas, depressão e outras patologias para as quais está indicado um agonista ou antagonista de 5-HT~ 1~.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8179098P | 1998-04-15 | 1998-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9901052A true BR9901052A (pt) | 2000-04-25 |
Family
ID=22166430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9901052-6A BR9901052A (pt) | 1998-04-15 | 1999-04-14 | Carboxamidas heterocìclicas. |
Country Status (10)
Country | Link |
---|---|
US (4) | US6277852B1 (pt) |
EP (1) | EP0957099B1 (pt) |
JP (1) | JP3224372B2 (pt) |
AT (1) | ATE228119T1 (pt) |
BR (1) | BR9901052A (pt) |
CA (1) | CA2268870C (pt) |
DE (1) | DE69903992T2 (pt) |
DK (1) | DK0957099T3 (pt) |
ES (1) | ES2188095T3 (pt) |
PT (1) | PT957099E (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2188095T3 (es) * | 1998-04-15 | 2003-06-16 | Pfizer Prod Inc | Carboxamidas heterociclicas. |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
EP1383496B1 (en) * | 2001-02-20 | 2008-10-01 | Dinan, Timothy Gerard | Treatment of fibromyalgia using pindolol |
US6979447B2 (en) * | 2001-03-30 | 2005-12-27 | Philadelphia Health And Education Corporation | Immunomodulation and effect on cell processes relating to serotonin family receptors |
US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
SK288015B6 (sk) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
US7194366B2 (en) * | 2001-10-19 | 2007-03-20 | Auburn University | System and method for estimating reliability of components for testing and quality optimization |
CN100413861C (zh) | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
AP2007004245A0 (en) | 2005-05-13 | 2007-12-31 | Virochem Pharma Inc | Compounds and methods for the treatment or prevention of flavivirus infections |
JP5498703B2 (ja) | 2006-01-23 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド |
EP2418210A1 (en) | 2006-04-13 | 2012-02-15 | Vertex Pharmceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
CN101495474A (zh) | 2006-05-23 | 2009-07-29 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的噻吩-甲酰胺类 |
JP2009538309A (ja) * | 2006-05-23 | 2009-11-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド |
DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
NZ576780A (en) | 2006-11-15 | 2011-12-22 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
EP3034494A1 (en) | 2007-08-15 | 2016-06-22 | President and Fellows of Harvard College | Heterocyclic inhibitors of necroptosis |
MX367469B (es) | 2010-06-07 | 2019-08-23 | Novomedix Llc | Compuestos furanilo y su uso. |
JPWO2013161871A1 (ja) * | 2012-04-25 | 2015-12-24 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
US9926286B2 (en) * | 2014-05-09 | 2018-03-27 | Shanghai Syncores Technologies Inc. Ltd. | Vortioxetine intermediate and synthesis process thereof |
WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
JP6929276B2 (ja) | 2015-10-06 | 2021-09-01 | プロテオステイシス セラピューティクス,インコーポレイテッド | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 |
BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
EP3366683A1 (en) * | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
FR2631625B1 (fr) * | 1988-05-17 | 1992-10-16 | Synthelabo | Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique |
US5130338A (en) * | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
FR2655988B1 (fr) * | 1989-12-20 | 1994-05-20 | Adir Cie | Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
CA2158457C (en) * | 1993-03-16 | 2001-04-17 | Bertrand Leo Chenard | Naphthalene derivatives |
JPH09504004A (ja) * | 1993-08-20 | 1997-04-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5ht1dレセプター拮抗薬用アミドおよび尿素誘導体 |
GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
ES2188095T3 (es) * | 1998-04-15 | 2003-06-16 | Pfizer Prod Inc | Carboxamidas heterociclicas. |
US6492385B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
-
1999
- 1999-03-25 ES ES99302288T patent/ES2188095T3/es not_active Expired - Lifetime
- 1999-03-25 DE DE69903992T patent/DE69903992T2/de not_active Expired - Fee Related
- 1999-03-25 PT PT99302288T patent/PT957099E/pt unknown
- 1999-03-25 DK DK99302288T patent/DK0957099T3/da active
- 1999-03-25 AT AT99302288T patent/ATE228119T1/de not_active IP Right Cessation
- 1999-03-25 EP EP99302288A patent/EP0957099B1/en not_active Expired - Lifetime
- 1999-04-12 JP JP10391799A patent/JP3224372B2/ja not_active Expired - Fee Related
- 1999-04-13 CA CA002268870A patent/CA2268870C/en not_active Expired - Fee Related
- 1999-04-14 US US09/291,352 patent/US6277852B1/en not_active Expired - Fee Related
- 1999-04-14 BR BR9901052-6A patent/BR9901052A/pt not_active Application Discontinuation
-
2001
- 2001-05-22 US US09/862,691 patent/US6537995B2/en not_active Expired - Fee Related
- 2001-05-22 US US09/862,932 patent/US6602874B2/en not_active Expired - Fee Related
-
2003
- 2003-06-20 US US10/601,209 patent/US20030232841A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK0957099T3 (da) | 2003-03-17 |
US20010041705A1 (en) | 2001-11-15 |
US6277852B1 (en) | 2001-08-21 |
EP0957099A3 (en) | 1999-11-24 |
ES2188095T3 (es) | 2003-06-16 |
US6537995B2 (en) | 2003-03-25 |
JP3224372B2 (ja) | 2001-10-29 |
US20030232841A1 (en) | 2003-12-18 |
EP0957099B1 (en) | 2002-11-20 |
ATE228119T1 (de) | 2002-12-15 |
US6602874B2 (en) | 2003-08-05 |
EP0957099A2 (en) | 1999-11-17 |
CA2268870A1 (en) | 1999-10-15 |
DE69903992T2 (de) | 2003-08-21 |
DE69903992D1 (de) | 2003-01-02 |
PT957099E (pt) | 2003-02-28 |
US20020002168A1 (en) | 2002-01-03 |
JPH11322711A (ja) | 1999-11-24 |
CA2268870C (en) | 2005-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0957099T3 (da) | Heterocykliske carboxamider | |
PT952154E (pt) | N-acil- e n-aroil-aralquilamidas | |
DK0931788T3 (da) | Metalloproteasehæmmere | |
DE69713402D1 (de) | Liganden des neuropeptids y | |
HK1054930A1 (en) | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents | |
ATE402149T1 (de) | Heterozyklische substituierte amide, deren herstellung und anwendung | |
DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
DE69708968D1 (de) | Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste | |
DE69323667T2 (de) | 4-substituierte 1,2,4-Triazolderivate | |
ATE237612T1 (de) | Benzofuranderivate | |
ID23053A (id) | Karboksamida yang digunakan sebagai agonis 5-ht <if> | |
BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
BR0201569A (pt) | 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7 | |
DK0821955T3 (da) | Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse | |
EA200001104A1 (ru) | Аскорбат пароксетина | |
EP1561744A3 (en) | Amine derivatives, process for producing the same and their use as antimycotic agent | |
SE9901237D0 (sv) | Novel use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |